This video discusses the mechanism of action of cancer therapies Gonadotropinreleasing hormone (GnRH) agonists.
#science #cancer #medicine

More videos coming soon. Please rate☝, comment, and subscribe☝ if you like them, so that I can make more! Please send through requests for topics to cover as well. What do you want to learn about? #scienceinmotion

Social
Check out other socials: TikTok   / scienceinmotion  
Instagram   / scienceinmotiongram  
Twitter   / sciencemotioner  
Facebook   / scienceinmotion114470440455167  
Website https://scienceinmotion.wixsite.com/s...

Music & images
Music thanks to: Vyond
Some images thanks to: Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License.
Some images designed by Freepik/vectorpouch/pch.vector/vectorpocket . Available from: www.freepik.com Some images adapted from
BioRender. Created with BioRender.com. Available from: https://biorender.com/
Some images designed by Pixabay, licensed under Creative Commons Attribution 3.0 Unported License. Available from: https://pixabay.com/
Some images purchased from Shutterstock. Available from: https://www.shutterstock.com/ Some footage/images purchased from
Storyblocks. Available from: https://www.storyblocks.com/

References
Howell A. Fulvestrant. In: Schwab M, editor. Encyclopedia of Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg; 2009. p. 116871.
Imamura Y, Sadar M. Androgen receptor targeted therapies in castrationresistant prostate cancer: Bench to clinic2016.
Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer. 2003;10(2):20916.
Yamaoka M, Hara T, Kusaka M. Overcoming Persistent Dependency on Androgen Signaling after Progression to CastrationResistant Prostate Cancer. Clinical Cancer Research. 2010;16(17):4319.
DrudgeCoates L. GnRH blockers: A changing paradigm in the management of prostate cancer2010. 8592
Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer. 2015;15:26
Brodie A, Sabnis G. Adaptive Changes Result in Activation of Alternate Signaling Pathways and Acquisition of Resistance to Aromatase Inhibitors. Clinical Cancer Research. 2011;17(13):4208.1.
Pietras RJ, MárquezGarbán DC. MembraneAssociated Estrogen Receptor Signaling Pathways in Human Cancers. Clinical Cancer Research. 2007;13(16):4672.
Makridakis N, Buchanan G, Tilley W, Reichardt J. Androgen metabolic genes in prostate cancer predisposition and progression2005. 2892903 p.
Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective CyclinDependent Kinase 4/6 Inhibitor in Various Solid Tumors. Clinical Cancer Research. 2017;23(13):3251.
Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, et al. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. Journal of Hematology & Oncology. 2017;10(1):97.
Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L, et al. The therapeutic role of fulvestrant in the management of patients with hormone receptorpositive breast cancer. The Breast. 2014;23(3):2018.
Nathan MR, Schmid P. A Review of Fulvestrant in Breast Cancer. Oncology and Therapy. 2017;5(1):1729.
cancer,oncology,mechanism of action,signalling,signaling,therapy,therapeutic,cell,breast cancer,estrogen,oestrogen,selective estrogen receptor modulator,receptor,DNA,nucleus,cell cycle